BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 16247746)

  • 1. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.
    el-Sayed MH; Shanab G; Karim AM; el-Tawil A; Black A; Dixon JS
    Pediatr Hematol Oncol; 2004 Mar; 21(2):145-56. PubMed ID: 15160513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
    Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
    Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
    Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
    J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
    Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
    Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
    Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
    Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
    Lalazar G; Rund D; Shouval D
    Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
    Coiffier B
    Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
    Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
    Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; AirĂ² P
    J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
    Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
    Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.